PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 11077646

Clinical trial results with MPA/E2C.

L P Shulman
View original source ↗Export metadata ↓

Abstract

Results of a multicenter, controlled U.S. trial that evaluated a new monthly combination injectable have confirmed that the injectable formulation is both highly effective and well tolerated. The results of the U.S. trial are consistent with clinical studies conducted in other countries by the WHO and suggest that this new contraceptive method will expand clinical options for preventing pregnancy. The specific advantages of the monthly injectable formulation include infrequent dosing, rapid reversibility and a degree of efficacy that rivals sterilization.

Explore related subjects

Clinical Trials, Phase III as TopicContraceptive Agents, FemaleDrug Administration ScheduleEstradiolFemaleHumansInjections, IntramuscularMedroxyprogesterone AcetateUnited StatesJournal ArticleReview

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

L P Shulman. 2000. Clinical trial results with MPA/E2C.. https://pubmed.ncbi.nlm.nih.gov/11077646/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2007

Squalene synthase inhibition: a novel target for the management of dyslipidemia.

A new class of compounds, known as squalene synthase inhibitors, has recently reached phase III clinical trials and may provide another therapeutic option for clinicians to improve risk management of low-density lipoprotein cholesterol (LDL-C). The clinical need for another LDL-C-lowering therapy is evident by the inability to achieve an LDL-C target of less than 70 mg/dL in the majority of very high-risk patients on statin monotherapy. Human clinical trial data with TAK-475, a novel and potent inhibitor of squalene synthase, have not yet been published.

Clinical Trials, Phase III as Topic↗
PubMed2006

[Herpes simplex virus vaccines: perspectives].

PURPOSE: Despite effective antiviral therapy, infection with herpes simplex virus (HSV) is a critical public health issue, particularly genital herpes by its social and psychological burden and its contribution to the neonatal herpes and possibly to the HIV/AIDS pandemic. CURRENT KNOWLEDGE: Many prophylactic and therapeutic vaccination approaches have been explored but no effective vaccine is presently available. In fact, as members of the Herpesviridae family, both HSV-1 and 2 types have genes involved in immune evasion. FUTURE PROSPECTS: Further research is needed to define determinants of immunity in order to design more effective vaccines.

Clinical Trials, Phase III as Topic↗